Literature DB >> 23698561

HIV-1 eradication strategies: design and assessment.

Janet D Siliciano1, Robert F Siliciano.   

Abstract

PURPOSE OF REVIEW: Recent developments have generated renewed interest in the possibility of curing HIV-1 infection. This review describes some of the practical challenges that will need to be overcome if curative strategies are to be successful. RECENT
FINDINGS: The latent reservoir for HIV-1 in resting memory CD4 T cells is the major barrier to curing the infection. The most widely discussed approach to curing the infection involves finding agents that reverse latency in resting CD4 T cells, with the assumption that the cells will then die from viral cytopathic effects or be lysed by host cytolytic T lymphocytes (CTLs). A major challenge is the development of in-vitro models that can be used to explore mechanisms and identify latency-reversing agents (LRAs). Although several models have been developed, including primary cell models, none of them may fully capture the quiescent state of the cells that harbour latent HIV-1 in vivo. An additional problem is that LRAs that do not cause T-cell activation may not lead to the death of infected cells. Finally, measuring the effects of LRAs in vivo is complicated by the lack of correlation between different assays for the latent reservoir.
SUMMARY: Progress on these practical issues is essential to finding a cure.

Entities:  

Mesh:

Year:  2013        PMID: 23698561      PMCID: PMC3963140          DOI: 10.1097/COH.0b013e328361eaca

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  57 in total

Review 1.  HIV latency.

Authors:  Robert F Siliciano; Warner C Greene
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

Review 2.  Primary cell models of HIV latency.

Authors:  Hung-Chih Yang
Journal:  Curr Opin HIV AIDS       Date:  2011-01       Impact factor: 4.283

3.  Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.

Authors:  Sifei Xing; Cynthia K Bullen; Neeta S Shroff; Liang Shan; Hung-Chih Yang; Jordyn L Manucci; Shridhar Bhat; Hao Zhang; Joseph B Margolick; Thomas C Quinn; David M Margolis; Janet D Siliciano; Robert F Siliciano
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

4.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

5.  Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.

Authors:  Hung-Chih Yang; Sifei Xing; Liang Shan; Karen O'Connell; Jason Dinoso; Anding Shen; Yan Zhou; Cynthia K Shrum; Yefei Han; Jun O Liu; Hao Zhang; Joseph B Margolick; Robert F Siliciano
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

6.  SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx.

Authors:  Nadine Laguette; Bijan Sobhian; Nicoletta Casartelli; Mathieu Ringeard; Christine Chable-Bessia; Emmanuel Ségéral; Ahmad Yatim; Stéphane Emiliani; Olivier Schwartz; Monsef Benkirane
Journal:  Nature       Date:  2011-05-25       Impact factor: 49.962

7.  Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART.

Authors:  Erin H Graf; Angela M Mexas; Jianqing J Yu; Farida Shaheen; Megan K Liszewski; Michele Di Mascio; Stephen A Migueles; Mark Connors; Una O'Doherty
Journal:  PLoS Pathog       Date:  2011-02-24       Impact factor: 6.823

8.  SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutières syndrome are highly susceptible to HIV-1 infection.

Authors:  André Berger; Andreas F R Sommer; Jenny Zwarg; Matthias Hamdorf; Karin Welzel; Nicole Esly; Sylvia Panitz; Andreas Reuter; Irene Ramos; Asavari Jatiani; Lubbertus C F Mulder; Ana Fernandez-Sesma; Frank Rutsch; Viviana Simon; Renate König; Egbert Flory
Journal:  PLoS Pathog       Date:  2011-12-08       Impact factor: 6.823

9.  Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.

Authors:  Sifei Xing; Shridhar Bhat; Neeta S Shroff; Hao Zhang; Joseph A Lopez; Joseph B Margolick; Jun O Liu; Robert F Siliciano
Journal:  J Antimicrob Chemother       Date:  2011-12-07       Impact factor: 5.790

10.  Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.

Authors:  N M Archin; A L Liberty; A D Kashuba; S K Choudhary; J D Kuruc; A M Crooks; D C Parker; E M Anderson; M F Kearney; M C Strain; D D Richman; M G Hudgens; R J Bosch; J M Coffin; J J Eron; D J Hazuda; D M Margolis
Journal:  Nature       Date:  2012-07-25       Impact factor: 49.962

View more
  45 in total

1.  Effect of the use of Galectin-9 and blockade of TIM-3 receptor in the latent cellular reservoir of HIV-1.

Authors:  Marta Sanz; Nadia Madrid-Elena; Sergio Serrano-Villar; Alejandro Vallejo; Carolina Gutiérrez; Santiago Moreno
Journal:  J Virol       Date:  2020-12-23       Impact factor: 5.103

2.  Reactivation Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific CD8+ T Cells.

Authors:  Victoria E K Walker-Sperling; Valerie J Cohen; Patrick M Tarwater; Joel N Blankson
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

Review 3.  Impact of Myeloid Reservoirs in HIV Cure Trials.

Authors:  Brooks I Mitchell; Elizabeth I Laws; Lishomwa C Ndhlovu
Journal:  Curr HIV/AIDS Rep       Date:  2019-04       Impact factor: 5.071

Review 4.  Role of Fc-mediated antibody function in protective immunity against HIV-1.

Authors:  George K Lewis
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

Review 5.  Antiretroviral treatment in HIV-infected infants and young children: novel issues raised by the Mississippi baby.

Authors:  Stephanie Shiau; Louise Kuhn
Journal:  Expert Rev Anti Infect Ther       Date:  2014-02-09       Impact factor: 5.091

6.  Sequence-specific alterations of epitope production by HIV protease inhibitors.

Authors:  Georgio Kourjian; Yang Xu; Ijah Mondesire-Crump; Mariko Shimada; Pauline Gourdain; Sylvie Le Gall
Journal:  J Immunol       Date:  2014-03-10       Impact factor: 5.422

7.  Exosomal Tat protein activates latent HIV-1 in primary, resting CD4+ T lymphocytes.

Authors:  Xiaoli Tang; Huafei Lu; Mark Dooner; Stacey Chapman; Peter J Quesenberry; Bharat Ramratnam
Journal:  JCI Insight       Date:  2018-04-05

8.  Elevated Plasma Viral Loads in Romidepsin-Treated Simian Immunodeficiency Virus-Infected Rhesus Macaques on Suppressive Combination Antiretroviral Therapy.

Authors:  Gregory Q Del Prete; Kelli Oswald; Abigail Lara; Rebecca Shoemaker; Jeremy Smedley; Rhonda Macallister; Vicky Coalter; Adam Wiles; Rodney Wiles; Yuan Li; Randy Fast; Rebecca Kiser; Bing Lu; Jim Zheng; W Gregory Alvord; Charles M Trubey; Michael Piatak; Claire Deleage; Brandon F Keele; Jacob D Estes; Joseph Hesselgesser; Romas Geleziunas; Jeffrey D Lifson
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

9.  Tissue myeloid cells in SIV-infected primates acquire viral DNA through phagocytosis of infected T cells.

Authors:  Nina Calantone; Fan Wu; Zachary Klase; Claire Deleage; Molly Perkins; Kenta Matsuda; Elizabeth A Thompson; Alexandra M Ortiz; Carol L Vinton; Ilnour Ourmanov; Karin Loré; Daniel C Douek; Jacob D Estes; Vanessa M Hirsch; Jason M Brenchley
Journal:  Immunity       Date:  2014-09-18       Impact factor: 31.745

10.  Identification of glycoproteins associated with HIV latently infected cells using quantitative glycoproteomics.

Authors:  Weiming Yang; Brooks Jackson; Hui Zhang
Journal:  Proteomics       Date:  2016-06-08       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.